Disaster Relief Contributions, New Medical Trials, Clinical Results and Employee Incentives - Research Report on UnitedHealth

   Disaster Relief Contributions, New Medical Trials, Clinical Results and
 Employee Incentives - Research Report on UnitedHealth Group, ACADIA, USANA,
                          Portola and Horizon Pharma

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 21, 2013

NEW YORK, November 21, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting
UnitedHealth Group, Inc. (NYSE: UNH), ACADIA Pharmaceuticals, Inc. (NASDAQ:
ACAD), USANA Health Sciences Inc. (NYSE: USNA), Portola Pharmaceuticals, Inc.
(NASDAQ: PTLA) and Horizon Pharma, Inc. (NASDAQ: HZNP). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

UnitedHealth Group, Inc. Research Report

On November 15, 2013, UnitedHealth Group, Inc. (UnitedHealth) announced that
United Health Foundation is partnering with Project HOPE, a US-based charity,
to help Filipinos affected by typhoon Haiyan receive urgent medical care and
critical medical supplies. According to UnitedHealth, the Foundation and
employees of the Company have committed at least $750,000 to fund Project
HOPE's efforts. The Company said that Project HOPE, working in conjunction
with the US Navy, will deliver medical supplies, and assemble and deploy teams
of volunteer nurses and physicians to disaster recovery sites in the
Philippines to deliver critical medical care to people affected by the
typhoon. United Health Foundation donations will directly fund the cost of
delivering these teams to the Philippines. The Full Research Report on
UnitedHealth Group, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/73e5_UNH

--

ACADIA Pharmaceuticals, Inc. Research Report

On November 14, 2013, ACADIA Pharmaceuticals, Inc. (ACADIA) announced that it
has initiated a Phase II feasibility trial designed to examine the efficacy
and safety of pimavanserin as a treatment for patients with Alzheimer's
disease psychosis (ADP). ACADIA stated that no drug is approved in the United
States to treat ADP and the off-label use of current antipsychotics is linked
to increased mortality, serious adverse events, and cognitive decline in
elderly patients with dementia-related psychosis. Executive Vice President of
Development and Chief Medical Officer Roger G. Mills, M.D. said, "We are
delighted to pursue this clinical study in collaboration with Professor
Ballard and King's College London. We believe that their unique clinical
research infrastructure and expertise will provide access to a pool of
well-characterized ADP patients and enable the use of a small and
geographically-focused group of highly trained raters, which we expect to
enhance study precision." The Full Research Report on ACADIA Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3eb7_ACAD

--

USANA Health Sciences Inc. Research Report

On November 12, 2013, USANA Health Sciences Inc. (USANA) announced that the
USANA True Health Foundation donated $20,000 to International Relief Teams
(IRT), a nonprofit international humanitarian organization, to aid victims of
Super Typhoon Haiyan. According to the Company, this is the third donation
sent to support relief efforts in the Philippines from the charitable
foundation established by USANA Health Sciences Inc., since its inception in
2012. USANA stated that the money donated by the Foundation for emergency aid
will serve 15,000 people for one week, which includes immediate survival
essentials such as clean water, water purification tablets and food. The Full
Research Report on USANA Health Sciences Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/ee40_USNA

--

Portola Pharmaceuticals, Inc. Research Report

On November 11, 2013, Portola Pharmaceuticals, Inc. (Portola) announced
initial results from a Phase 2 proof-of-concept study of andexanet alfa, its
investigational Factor Xa inhibitor antidote, in healthy volunteers who were
administered the Factor Xa inhibitor XARELTO (rivaroxaban). According to the
Company, results from the first two dosing cohorts of the study demonstrated
that andexanet alfa is able to dose-dependently reverse the anticoagulant
effects of XARELTO. Portola informed that these data, as well as data from
additional cohorts evaluating higher doses of andexanet alfa, will be
presented in a poster session on December 9, 2013 at the 55th American Society
of Hematology (ASH) Annual Meeting and Exposition, which will be held in New
Orleans from December 7, 2013 to December 10, 2013. The Full Research Report
on Portola Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/102f_PTLA

--

Horizon Pharma, Inc. Research Report

On November 12, 2013, Horizon Pharma, Inc. (Horizon Pharma) announced that on
November 7, 2013 the Compensation Committee of its Board of Directors approved
the grant of inducement stock options to purchase an aggregate of 156,550
shares of common stock to 26 new employees. The Company stated that each stock
option has an exercise price per share equal to $3.74, the fair market value
on the grant date, and vests over four years, with 25% of the shares vesting
on the one-year anniversary of the applicable vesting commencement date and
1/48 of the shares vesting monthly thereafter, subject to the new employee's
continued service relationship with the Company. Horizon Pharma also mentioned
that each stock option has a ten year term and is subject to the terms and
conditions of the Company's 2011 Equity Incentive Plan and the stock option
agreement pursuant to which the option was granted. The Full Research Report
on Horizon Pharma, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/05ea_HZNP

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)